TY - JOUR
T1 - Deep phenotyping as a contribution to personalized depression therapy
T2 - the GEParD and DaCFail protocols
AU - Lichter, Katharina
AU - Klüpfel, Catherina
AU - Stonawski, Saskia
AU - Hommers, Leif
AU - Blickle, Manuel
AU - Burschka, Carolin
AU - Das, Felix
AU - Heißler, Marlene
AU - Hellmuth, Anna
AU - Helmel, Jaqueline
AU - Kranemann, Leonie
AU - Lechner, Karin
AU - Lehrieder, Dominik
AU - Sauter, Amelie
AU - Schiele, Miriam A.
AU - Vijayakumar, Vithusha
AU - von Broen, Michael
AU - Weiß, Carolin
AU - Morbach, Caroline
AU - Störk, Stefan
AU - Gelbrich, Götz
AU - Heuschmann, Peter U.
AU - Higuchi, Takahiro
AU - Buck, Andreas
AU - Homola, György A.
AU - Pham, Mirko
AU - Menke, Andreas
AU - Domschke, Katharina
AU - Kittel-Schneider, Sarah
AU - Deckert, Jürgen
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/5
Y1 - 2023/5
N2 - Depressive patients suffer from a complex of symptoms of varying intensity compromising their mood, emotions, self-concept, neurocognition, and somatic function. Due to a mosaic of aetiologies involved in developing depression, such as somatic, neurobiological, (epi-)genetic factors, or adverse life events, patients often experience recurrent depressive episodes. About 20–30% of these patients develop difficult-to-treat depression. Here, we describe the design of the GEParD (Genetics and Epigenetics of Pharmaco- and Psychotherapy in acute and recurrent Depression) cohort and the DaCFail (Depression-associated Cardiac Failure) case–control protocol. Both protocols intended to investigate the incremental utility of multimodal biomarkers including cardiovascular and (epi-)genetic markers, functional brain and heart imaging when evaluating the response to antidepressive therapy using comprehensive psychometry. From 2012 to 2020, 346 depressed patients (mean age 45 years) were recruited to the prospective, observational GEParD cohort protocol. Between 2016 and 2020, the DaCFail case–control protocol was initiated integrating four study subgroups to focus on heart-brain interactions and stress systems in patients > 50 years with depression and heart failure, respectively. For DaCFail, 120 depressed patients (mean age 60 years, group 1 + 2), of which 115 also completed GEParD, and 95 non-depressed controls (mean age 66 years) were recruited. The latter comprised 47 patients with heart failure (group 3) and 48 healthy subjects (group 4) of a population-based control group derived from the Characteristics and Course of Heart Failure Stages A–B and Determinants of Progression (STAAB) cohort study. Our hypothesis-driven, exploratory study design may serve as an exemplary roadmap for a standardized, reproducible investigation of personalized antidepressant therapy in an inpatient setting with focus on heart comorbidities in future multicentre studies.
AB - Depressive patients suffer from a complex of symptoms of varying intensity compromising their mood, emotions, self-concept, neurocognition, and somatic function. Due to a mosaic of aetiologies involved in developing depression, such as somatic, neurobiological, (epi-)genetic factors, or adverse life events, patients often experience recurrent depressive episodes. About 20–30% of these patients develop difficult-to-treat depression. Here, we describe the design of the GEParD (Genetics and Epigenetics of Pharmaco- and Psychotherapy in acute and recurrent Depression) cohort and the DaCFail (Depression-associated Cardiac Failure) case–control protocol. Both protocols intended to investigate the incremental utility of multimodal biomarkers including cardiovascular and (epi-)genetic markers, functional brain and heart imaging when evaluating the response to antidepressive therapy using comprehensive psychometry. From 2012 to 2020, 346 depressed patients (mean age 45 years) were recruited to the prospective, observational GEParD cohort protocol. Between 2016 and 2020, the DaCFail case–control protocol was initiated integrating four study subgroups to focus on heart-brain interactions and stress systems in patients > 50 years with depression and heart failure, respectively. For DaCFail, 120 depressed patients (mean age 60 years, group 1 + 2), of which 115 also completed GEParD, and 95 non-depressed controls (mean age 66 years) were recruited. The latter comprised 47 patients with heart failure (group 3) and 48 healthy subjects (group 4) of a population-based control group derived from the Characteristics and Course of Heart Failure Stages A–B and Determinants of Progression (STAAB) cohort study. Our hypothesis-driven, exploratory study design may serve as an exemplary roadmap for a standardized, reproducible investigation of personalized antidepressant therapy in an inpatient setting with focus on heart comorbidities in future multicentre studies.
KW - Affective disorders
KW - Biomarkers
KW - Brain–heart interaction
KW - Major depressive disorder
KW - Predictive markers
UR - https://www.scopus.com/pages/publications/85150627908
U2 - 10.1007/s00702-023-02615-8
DO - 10.1007/s00702-023-02615-8
M3 - Article
C2 - 36959471
AN - SCOPUS:85150627908
SN - 0300-9564
VL - 130
SP - 707
EP - 722
JO - Journal of Neural Transmission
JF - Journal of Neural Transmission
IS - 5
ER -